Dicerna Pharmaceuticals Logo

Email this page: News Release

Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 (PH1) in Healthy Volunteers

For security reasons, registration is required before you can use this feature.
* Indicates required field